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TITLE: 
Bronchial Colonisation and Inflammation in Patients with Clinically 
Stable Bronchiectasis-Microbiological Pattern and Risk Factors 
AUTHORS: 
Dr.R.Nedunchezhian, Prof.Dr.D.Ranganathan, 
Prof.Dr.A.Mahilmaran, Dr.V.Sundhar 
Institute of Thoracic Medicine, Madras Medical College 
INTRODUCTION: 
Bronchiectasis is a chronic pulmonary disease characterized by an 
abnormal irreversible dilatation of one or more bronchi often with wall 
thickening.  The current view of the pathogenesis of Bronchiectasis considers 
initial colonization of the lower respiratory tract by different microorganisms as 
the first step leading to inflammatory response characterized by neutrophil 
migration within the airways and secondary secretion of variety of tissue 
damaging oxidants and enzymes such as neutrophil elastase, myeloperoxidase 
and cytokines [interleukins] . Persistence of microorganisms in the airways 
because of impairment in mucus clearance may lead to a vicious circle of events 
characterized by chronic bacterial colonization, persistent inflammatory reaction 
and progressive tissue damage and morbidity life. 
ABSTRACT: 
In order to evaluate the Bacterial colonisation and level of bronchial 
inflammation in relation with bacterial colonisation; we did bronchoalveolor 
lavage of patients admitted with HRCT Chest[taken within 3 months] evidence 
of bronchiectasis and fulfill with inclusion criteria of study. The obtained 
sample was divided into 3parts-One part was sent to microbiology for bacterial 
culture ,second one was sent to pathology for Total and Differential cell count 
estimation and third part was centrifuged and stored in 2 to 8'C temperature for 
IL-8 estimation 
METHOD OF STUDY:  
Continuous prospective study 
RESULTS:   
Among 90 study population analysis showed females were 58% and 
males were 42%. Cylindrical bronchiectasis 53%, followed by cystic 
bronchiectasis36% in predominance: and positive culture growth rate for 
sputum samples were 68% and BAL samples were 77%.The micro organisms 
isolated predominantly were H.influenza, Pseudomonas, Streptococci, 
Staphylocci and etc. Regarding airway inflammation, the total counts of BAL 
fluid were increased in all the patients with slight higher level in positive culture 
growth patients with slight Neutrophilic predominance. [90-210X10*3 cells in 
range and 120x10*3 cells in median]. The IL-8 measured showed increased 
level in all three groups comparing control groups indicating earlier 
establishment of inflammation in bronchiectasis. [81-835pg/dl in range and 
556pg/dl in median] 
CONCLUSION:  
A. The risk factors identified for increased colonisation were 1.long 
duration of symptoms 2.Cystic and Varicose bronchiectasis 3. Presence of  
alcoholism and smoking   
B. Sputum culture is non invasive, alternative to broncho alveolar lavage 
fluid culture.  
KEY WORDS: 
Bronchiectasis, Bacterial colonisation, Inflammation 
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INTRODUCTION 
Bronchion-Greek word means wind pipe1 
ektasis-means stretching out1 
Bronchiectasis is a disease in which patients spends morbid life 
having dyspnoea and productive, often foul smelling sputum which 
produces social isolation and depressive states.2. In 1819 Rene Theophile 
Laennec first discovered Bronchiectasis in post-mortem examination of 
infant body who died of whooping cough1, and he described, 'dilated 
bronchi lose their natural shape and present themselves under the form of 
cavity , capable of containing hemp seed, a cherry-stone, an almond, or 
even a walnut. The famous patient Williams Osler who died of road 
traffic accident on 1919, had respiratory symptoms for many years 
,Dr.George Gibson described the bronchiectatic changes of William Osler 
lungs on post mortem examination with bronchography1,. 
In 1950 Lynne Reid described the pathological types of 
bronchiectasis with bronchography in 45 patients1,3,7  
ICD-9 is the international disease classification code. 
Article in European respiratory journal april-2009 titled as 
mortality rate in bronchiectasis patients2, states the mortality rate of 
bronchiectasis in 12 year follow up period is 29.7% in the age group at 52 
2 
 
years. 70% cause of death in bronchiectasis is due to respiratory tract 
infection leading to respiratory failure2,4. The acute exacerbation of 
bronchiectasis is mainly due to growth of micro organisms and newer 
therapies like hypertonic solution like mannitol, Normal saline (up to 
maximum 7%) nebulisation and inhaled ciprofloxacin, gentamycin are 
under trial in reducing the exacerbation. By eliminating the micro 
organisms in bronchiectasis, the inflammation of airways and 
deterioration of lung function can be reduced; there by we can lead the 
bronchiectasis patients for morbidity nil life5,6 
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REVIEW OF LITERATURE 
The primary mode of search for articles in this review was through 
the bronchiectasis related articles in journals like,' Thorax.bmj on dec 13 
2013, ATS journals 1st Nov 2011, European Respiratory journal 2009, 
Journal of Inflammation Research 2013: 6 1-11 and from internet data 
bases and Google scholar. The general search terms were ,'Bacterial 
colonisation and inflammation, Exacerbation of Bronchiectasis , and 
Newer therapies in Bronchiectasis.',Immunology of Bronchiectasis, 
Broncho alveolar lavage technique, Microbiology of Bronchiectasis, Cell 
count in BAL fluid of Bronchiectasis, HRCT in Bronchiectasis in 
identifying aetiology, Pulmonary function in Bronchiectasis'. 
The articles that were excluded from search are  
1. The articles in language other than English for lack of 
comprehension 
2. The articles based on drug trials in bronchiectasis 
 
 
 
 
4 
 
EPIDEMIOLOGY 
The prevalence of Bronchiectasis in United States was 1.5/1000 
cases in 1956, now the exact incidence of this disease is not clearly 
known. Now it is reduced due to 
1. Improvement in living conditions of people  
2. Frequent and early use of antibiotics  
3. Childhood immunisation.1,3,7 
But in countries with poor socio economic conditions and less 
health care generally available, bronchiectasis remains the major cause of 
morbidity and mortality. Pamela J.University of Chicago described as 
High prevalence of bronchiectasis has been reported in native Americans 
of North America, New Zealand and Western Samoans.1,2,3 In U.S the 
prevalence of Non cystic fibrosis bronchiectasis in >65 years is 
1106/100,000 and the prevalence increased to 8.7% from 2000-2007 in 
U.S. The prevalence of bronchiectasis is increased with increased age, in 
females and in Asian population. However it is unclear whether these 
differences are due to genetic predisposition to bronchiectasis or 
environmental factors are responsible1,3,7.As per GOLD guidelines; on 
HRCT Chest investigation of chronic obstructive pulmonary disease 
patients, bronchiectasis was identified in 53% of patients .2,4 
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BRONCHIECTASIS 
DEFINITION 
Bronchiectasis is defined as abnormal permanent destruction and 
dilatation of one or more bronchi, often with wall thickening 1,3,7 
 
PREVALENCE IN GENDER 
Females have high prevalence than males, the exact reason not 
clear: May be due to altered inflammatory immune response in females 
and environmental genetic and anatomical differences1,3,7 
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PATHOPHYSIOLOGY 
Chronic bronchial sepsis has been used to describe the chronic 
bacterial infection of the impaired mucociliary action leads to microbial 
infection of lower respiratory tract that leads to release of inflammatory 
mediators. Sepsis is the condition in which bacteraemia occurs, where as 
this is rare in bronchiectasis because an exuberant immune response 
confines the infections to the lung.3,8,9,10 In bronchiectasis, there is chronic 
inflammation in which lymphocytes predominate in the bronchial wall 
and Neutrophils in the lumen. As well as B Lymphocytes, plasma cells 
and CD4 T lymphocytes in the follicles, there is a well developed cell 
mediated immunity, with increased numbers of activated T lymphocytes, 
mainly of the suppressor/cytotoxic CD8 phenotype, antigen processing 
cells and macrophages. A proportion of the CD8 cells express a marker 
for cytolytic potential3,11-17 
 
Mucus is poorly cleared from the bronchiectatic areas for several 
reasons. There is pooling in the abnormal dilated airways; ciliated cells 
are lost when the epithelium is damaged and mucus is less elastic more 
viscous and forms a vicious cycle.3,7,18,19 . 
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Coles hypothesis 
 
 
 
Coles hypothesis explained the vicious cycle in bronchiectasis. In 
bronchiectasis, impairment of mucociliary clearance due to chronic 
inflammation and some congenital causes leads to microbial colonisation 
of airways with poor elimination of microbes and secretions, leads to 
architectural damage leading to stagnation of secretion and this stagnation 
leads to microbial infections1,3. 
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Large number of Neutrophils are attracted from the blood stream 
into the bronchial lumen in response to bacterial infection, by 
chemotactic products of bacteria themselves and also mediators from the 
host cells.[e.g, interleukin-8,C5a, Tumour necrosis factor alpha, 
leukotriene B4,]. Persistence of micro organisms leads to persistent 
Neutrophilic chemotaxis that leads to liberation of tissue destroying 
enzymes and cytokines like Proteinase,Elastase,Myeloperoxidase 
,Tumour necrosis factor alpha[TNF alpha], and Interleukins 6,8,10,13. 
Proteinase, Elastase inhibits opsonin and destroys not only elastin but 
also destroys muscle layer of bronchi that is replaced by fibrous tissue 
leading to airway modelling,.7-10,11-17 Serum levels of intercellular 
adhesion molecule(ICAM-1) and vascular adhesion molecule (VCAM-1) 
are elevated suggesting the endothelial activation occurs, probably within 
lung13-17. The cell counts in broncho alveolar fluid in normal people is 
85% alveolar macrophages, 14% Lymphocytes and 1% will be 
Neutrophils and Eosinophils.1,3,7 
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In bronchiectasis the sub segmental airways are permanently dilated, 
tortuous and partially or totally obstructed by copious amounts of 
secretion. Structural proteins are lost from the bronchial wall and there is 
variable amount of fibrosis. The elastin layer of the wall is deficient or 
absent and the muscle and cartilage layer also shows signs of destruction. 
These changes weakens the wall leading to distortion of normal 
architecture.7,11-12,20 
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AETIOLOGY:  
Congenital/Acquired1,3,7 
Congenital causes: 
Ciliary dysfunction-kartagener syndrome, 
 Cystic fibrosis 
Mounier khun syndrome,  
William Campbell syndrome 
Young's syndrome,  
Yellow nail syndrome 
Alpha 1 anti trypsin deficiency 
Primary immunodeficiency -Hypogammaglobulinemia 
Secondary immunodeficiency-Malignancy 
                                                 -post transplantation    
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Acquired causes: 
a. Post infectious- 
1. Bacterial-Bordetella pertusis,  
Staphylococcus aureus 
Klebsiella pneumoniae,  
Hemophilus influenza 
Streptococcus pneumoniae, 
 Mycobacterium tuberculosis 
Mycobaterium avium intracellularae. 
2. Viral-Measles, Adeno and Herpes virus  
3. Fungal-Allergic bronchopulmonary aspergillosis 
 4. Parasitic-Trypanosomiasis 
b.Post aspiration and inhalation injury 
c.Connective tissue disease-Rheumatoid arthritis,Sjogren syndrome, 
d.Autoimmune disease-Primary biliary cirrhosis. 
e.Inflammatory bowel disease-Ulcerative colitis and Crohns disease 
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MICROBIOLOGY OF BRONCHIECTASIS: 
C.Agusti et al study in Thorax.2002:57:1-15 and U .S Investigation 
into aetiology of bronchiectasis separately evaluated the microbiological 
flora from the bronchiectasis patients in 1.Sputum samples 2.Broncho 
alveolar lavage fluid and 3.Protected specimen brush. C.Agusti et al study 
identified the micro organisms as below 
In sputum samples-26 potentially pathogenic micro organisms 
from 22 patients(52%) and 48 non potentially pathogenic micro 
organisms from 25 patients in total 112%; in 59 Broncho alveolar lavage 
fluid samples , 38 potentially pathogenic micro organisms from 33 
patients (56%) and 25 non potentially pathogenic micro organisms from 
33 patients (32%) ; and in 75 Protected specimen brush samples 61 
potentially pathogenic micro organisms (75%) and 36 non pathogenic 
potentially pathogenic micro organisms from 22 patients (29%) and the 
concordant value for sputum and BAL culture was 75% with p value 
=0.00111,12,20. 
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In U.S Investigation into aetiology of bronchiectasis study isolated 
90% of micro organisms colonisation in 106 patients. Both studies states 
that in bronchiectasis infections are usually caused by bacterial species 
that form part of the nasopharyngeal flora like,H.infleunza, Morexella 
catarrhalis, Streptococus pneumonia and the opportunistic pathogen 
Pseudomonas. The initial infection by Pseudomonas aeruginosa is usually 
with a non mucoid strain, which becomes mucoid when the infection is 
chronic. P.aeruginosa is thought to be directly involved in the 
deterioration of pulmonary function i,e associated with extensive lung 
disease and severe airflow obstruction. Isolation of P.aeruginosa could be 
just marker of disease severity rather than actual disease. When chronic 
bronchial infection occurs with commensal or opportunistic bacteria it 
reflects the severity of impairment of lung defences rather than the 
virulence of organisms.3,7,21,22 
Both studies classified the micro organisms into potentially 
pathogenic micro organisms [PPM] , and Non potentially pathogenic 
micro organisms[Non PPM] depending upon the disease producing 
capacity. 
King and Colleagues also isolated and classified the micro 
organisms. 
14 
 
Potentially pathogenic micro organisms [PPM]: Following micro 
organisms were classified as PPM8-12 
1. Hemophilus influenza 47% and para influenza 5% 
2. Pseudomonas [various strains] 12% 
3. Klebsiella species 6% 
4. Staphylococcus aureus 4% 
5. Morexella catarrhalis 8% 
6. Escherichia coli 3% 
7. Streptococcus pneumoniae 7% 
8. Proteus species 
9. Aspergillus species 
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Non potentially pathogenic micro organisms [NonPPM]: The following 
micro organisms were classified as non PPM.3,7,11 
1. Streptococcus viridans  
2. Corynebacterium species 
3. Coagulase negative Staphylococcus aureus[CONS] 
4. Enterococcus 
As per the previous studies the cut off point for significant bacterial 
culture growth positivity for protected specimen brush [PSB] was more 
than 10x2 cfu; for Sputum 10x5 cfu and for Broncho alveolar lavage fluid 
was more than 10x3 cfu 3,7,8,11,12 
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AIRWAY INFLAMMATION IN BRONCHIECTASIS 
In this study, inflammation of airway was studied mainly based on 
the following two studies. 
1. Joaquim Angrill et al study in .ATS-volume 164.issue 9, Nov-1-2001  
2. David A Bergin .Journal of inflammation research 2013:6 1-11 
David A Bergin et al study did Interleukin4, 10 and cell counts in 15 
microlitre of BAL fluid at 405nm, from 45 bronchiectasis patients and the 
values were as below.  
Total cell counts- median cell count was 23x103 cells and 10-
1086x103 cells in range from Non colonising patients to potentially 
pathogenic micro organisms growth patients; and the Neutrophilic pattern 
was observed in 67(in median) 56-88 (in range) patients. Macrophage 
pattern was observed in 27(median) 8-38(in range)11,12,20. 
Interleukin 4: 28.3pg/ml (in median) against the control 2.12pg/ml 
with p value =0.9. Interleukin 10: 151.3pg/ml (in median) against control 
0.1pg/ml with p value =0.05.11,12,20 
Jouquim Angrill et al study also evaluated the bronchial 
inflammation and the values were as below. 
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Total count: in control group 1.1x105 cells in median 
in Non colonised group-24.75x105 cells in median 
  in PPM growth group - 22x105 cells in median11,12,20 
Interleukin-8: in control -0-31pg/ml in range. 195pg/ml in PPM 
group (median) and 0-5520pg/ml in range with p value =0.00111,12,20. 
Above studies states that Non colonised patients showed a more intense 
bronchial inflammatory reaction than did control subjects. This 
inflammatory reaction was exaggerated in patients colonised by micro 
organisms with potential pathogenicity, with a clear relationship the 
bronchial bacterial load and showed that patients with bronchiectasis in a 
stable clinical condition present an active neutrophilic inflammation in 
the airways that is exaggerated by the presence of MPP, and the higher 
the bacterial load the more intense the inflammation.23-26  
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RISK FACTORS FOR BACTERIAL COLONISATION 
J.Angrill et al study states that, the people with normal pulmonary 
function i.e. with FEV1> 80% were present in n=24 of the study 
population. FEV1< 65% was observed in n=11 of the study population 
and the later group had higher BAL level of interleukin 1beta (115pg/ml), 
TNF-alpha (41pg/ml), IL-10 (7.3pg/ml) suggesting the relationship 
between the level of inflammation and poor pulmonary function. A 
significant direct relationship between the bacterial load and the 
Neutrophils and Interleukin-8 was observed i.e. more bacterial load leads 
to more inflammation11,12,20,29,30 
C Agusti study et al states that following factors were associated 
with increased risk of microbial colonisation. 
1. presence of chronic expectoration[long duration of symptoms] 
 2. evidence of cystic and varicose bronchiectasis in HRCT scan 
 3. diagnosis of bronchiectasis < 14 years of age 
4. presence of sinusitis and lung function FEV1< 80%.  
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Smoking increases the bacterial infections of Respiratory Tract;  
by inhibition of Monocytes,Macrophages and Dendritic cells activity 
[innate immunity], in smokers immunoglobulin E will be increased with 
lowered level of immunoglobulin G[altered adaptive immunity]and 
Impairment of ciliary functions.31 
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INTERLEUKINS -8 
Interleukin-8 (IL-8) is a member of a family of structurally-related 
low molecular weight proinflammatory factors known as chemokines. IL-
8 is produced by stimulated monocytes but not by tissue macrophages 
and Tlymphocytes.1,3,7,11. IL-8 is a non-glycosylated protein of 8 kDa (72 
amino acids). It is produced by processing of a precursor protein of 99 
amino acids. Eventhough different interleukins were liberated into the site 
of inflammation, IL-8 which is mainly responsible for Neutrophilic 
chemotaxis in bronchiectasis.1,3,7,11,32-36 Previous studies stated that 
Broncho alveolar lavage fluid level of IL-8 was significantly raised in 
Bronchiectasis in comparison with serum levels of IL-8; and it showed 
the inflammation was compartmentalised11,12,20,32-36 
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DEFINITIONS FOR  
1.Stable Bronchiectasis 
C Agusti et al study described, patients with bronchiectasis who 
have not received antibiotics within 4 weeks and not hospitalised within 2 
months were labelled as stable Bronchiectasis11,12,20. 
2.Good quality sputum 
Murray Washington criteria grade v i.e. >25 Neutrophils and <10 
epithelial cells per field using low power magnification lens[x100] was 
described as good quality sputum11,12,20. 
3.HRCT Chest score 
[Based on Reiffe and colleagues criteria for HRCT Chest scoring in 
bronchiectasis] The presence and extent of bronchiectasis in each lobe 
was graded using a scale from 0 to 3; where 0=no bronchiectasis, 
1=involvement of one segment, 2=involvement of more than one segment 
and 3= presence of cystic bronchiectasis. By considering lingula as a 
separate lobe maximum points were 18. The score in percentage was 
derived by total number of points divided by maximum points multiplied 
by 100]11,12,20 
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BRONCHIECTASIS TYPES:[REID CLASSIFICATION] 
1.Tubular/Cylindrical  
Mildform.Regularly outlined, dilated in diameter or straight walls 
with abrupt end37,38.Cylindrical bronchiectasis is much more common 
nowadays in which the damage to bronchial wall is less severe. This type 
of bronchiectasis is usually bilateral and may be diffuse has been 
described as modern bronchiectasis.1,3,7,39,40 
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2.Varicose/Fusiform 
Irregular dilatation with outpouching and tortousity of airways 
[string of pearls appearance]17. In Varicose bronchiectasis there are local 
constrictions superimposed on cylindrical changes1,3,7,39,40. 
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3.Cystic/Saccula 
Severe form. Cystic dilatation of airways[bunch of grapes 
appearance]37-38 Cystic or saccular bronchiectasis in which severe loss of 
bronchial wall structure leads to large, balloon like dilatation, are now 
infrequently seen in developed countries. This bronchiectasis often 
follows severe lung infection and was characterised by production of 
large volume of sputum and finger clubbing.1,7,39,40  
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Other type  
Traction bronchiectasis occurs in fibrotic lung conditions such as 
fibrosing alveolitis in which the airways are pulled apart by the fibrous 
process.1,7,39,40 
 
 
Picture-7: Showing the Traction bronchiectasis in HRCT Chest. 
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DIAGNOSIS  
It is based on History, clinical examination and is confirmed by 
radiology1,3,7 
1. History of Chronic expectoration [purulent or Mucopurulent sputum] 
2. Positive Family history and consanguinity1,3,7 
On examination: bilateral pan digital finger clubbing,Halitosis1,3,7 
On auscultation: coarse leathery persistent crackles heard on both 
phases of respiration. Chest X ray: Ring shadows on end on view of 
airway. Tramline shadow on side on view of airway1,3,7,11,12. 
HRCT Chest: the investigation of choice 
1.The non tapering of bronchi >2cm from costal pleura  
2.Visualisation of bronchi within 1 cm to the visceral pleura  
3.Bronchial wall dilatation and thickening seen as signet ring sign 
Other signs- Mosaic attenuation pattern, Tree in bud appearance, 
Mucus plugging of airways, lobar volume loss.39,40 
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BRONCHO ALVEOLAR LAVAGE TECHNIQUE 
1.SAMPLING OF CELLS 
Broncho alveolar lavage with using Fiber optic bronchoscope was 
introduced on 1974 by Raynolds and Newballs. BAL is a safe procedure 
in human research and clinical implications. In BAL sampling 1.the cells 
in alveolus in contact with broncho alveolar lavage fluid are sampled, 2. 
the cells in alveoli not in contact with BAL fluid are not sampled , 
3.airway cells that lines the bronchial walls are sampled by washing41-46. 
2.UNDERLYING CONDITION 
The broncho alveolar lavage is useful in following conditions as 
diagnostic and therapeutic 
1.Interstitial lung diseases-  
2.In identifying Infectious aetiology including Pneumocystis pneumonia 
3.Asthma and Chronic obstructive pulmonary disease 
4.Pulmonary alveolar proteinosis 
In Cigarette smokers, BAL fluid macrophages will be increased 
often to 10 fold than non smoker41-46 
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3.SUCTION PRESSURE 
During BAL if we use high pressure suction, the airway wall will 
collapse. So the recommended suction pressure is < 60mmHg to 100 
mmHg.41-46 
4.VOLUME OF FLUID INSTILLED 
The cellular and protein component of BAL fluid will vary 
depending upon the amount of fluid instilled and the amount of fluid 
aspirated. For good cell count and protein analysis, at least 100 ml of 
fluid [0.9 % Normal saline is ideal] to 150ml of fluid to be used. About 
50 to 60 % of instilled fluid should be aspirated41-46 
5.HANDLING OF ASPIRATED FLUID 
The first aliquot about 20 ml contain more epithelial cells and less 
cells than subsequent aliquot, So for estimating cell count and protein, the 
first aliquot 20ml is better to be discarded ; But in microbiological 
analysis , the first aliquot to be sent to Microbiology for better result as 
the first aliquot contain more epithelial cells and debris 41-46 
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6.POSITION OF PATIENT 
As the broncho alveolar lavage is mainly dependant on gravity 
aided drainage, patient position can affect the lavage. Supine position is 
the ideal position for lavage with gravity aided and less suction 
pressure.41-46 
7.AREA OF LAVAGE 
Previously the BAL was done mainly from lower lobes. But in 
diffuse lung disease BAL should be done from the disease affected parts 
of lung and even from all lobes of lung.41-46 
8.STORAGE OF FLUID 
The obtained fluid by broncho alveolar lavage is to be stored in 2 
to 4 degree Celsius for cell count and protein determination.41-46 
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9.SAFETY OF BAL 
Broncho alveolar lavage is safe and effective in human research 
and clinical conditions like Asthma, COPD,Ventilator associated 
pneumonia and Adult respiratory distress syndrome. The important 
complication associated with this procedure is 1. Hypoxia 2. Fever. The 
bronchoscopist should get a detailed history of patient i.e. previous 
procedure and complications, trauma, associated medical conditions and 
medicines using, coagulation studies and ,Renal and Liver function test 
for safe procedure..However the meticulous asepsis technique is to be 
practised always.41-46 
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THE MICROSCOPIC PICTURES OF MICRO ORGANISMS 
Staphylococcus aureus ; Streptococcus pneumoniae 
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H.influenza and Pseudomonas aeruginosa 
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Klebsiella pneumoniae and Morexella catarrhalis 
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British Thoracic Society Guidelines 
1.Sputum Microbiology: 
1. All children and adults with bronchiectasis should have assessment of 
lower respiratory tract microbiology 
2. Persistent isolation of staphylococcus aureus and or pseudomonas leads 
to consideration of underlying ABPA or cystic fibrosis 
3. To get the maximum yield of H.influenza and Streptococcus 
pneumoniae the sputum sample should reach the lab within 3 hours 
2.Pharmacotherapy 
1.Inhaled B2 agonist and anti cholinergic therapy will improve lung 
symptoms and function 
2.No role of routine use of methylxanthines in bronchiectasis 
3.No evidence of use of interleukin receptor antagonist or other anti 
inflammatory drugs 
4.It does not support routine use of inhaled corticosteroid  in adults( out 
side of use for those having additional bronchial asthma) 
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3.Indications for Bronchoscopy  
[BTS] British Thoracic Society guidelines recommends FOB in 
following conditions not as routine 
In localised bronchiectasis-to exclude proximal obstruction 
In patients whose serial sputum culture is negative and who is not 
responding to treatment and HRCT features suggestive of Atypical 
mycobacterial infection and whom sputum culture is negative 
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STUDY JUSTIFICATION: 
The main Goal in treating Bronchiectasis[as per BTS guideline]  
1.To identify and treat the underlying cause to prevent disease 
progression  
2.To improve or maintain lung function  
3.To reduce exacerbation  
4. To improve quality of life by reducing daily symptoms 
Hence this study aims to evaluate the microbiological pattern in patients 
with bronchiectasis and study the appropriate antibiotic to be 
administered to eliminate the bacterial colonisation and reduce the 
bronchial inflammation. Comparing previous studies in this study, i have 
excluded the pharyngeal swab culture because of, while on doing 
pharyngeal swab the violent coughing of patients, the chance investigator 
developing infection from patient is high; and Protected Specimen Brush 
is also not done due to cost; In this study sputum culture and 
Bronchoalveolar fluid culture were done and compared the concordant 
value for sputum and broncho alveolar lavage fluid culture. 
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AIMS & OBJECTIVES 
1.To compare the Sputum culture and Bronchoalveolar fluid culture yield 
2.To analyse the potential risk factor associated with presence of 
pathogenic microorganism in airway 
3.To evaluate the Bronchial inflammatory response and its relationship to 
bacterial colonisation in Bronchiectasis 
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STUDY DESIGN 
This is prospective continuous study to evaluate 1.the Bacterial 
flora from Lower Respiratory tract of Bronchiectasis patients who 
attended the Thoracic medicine outpatient department with diagnosis 
confirmed by radiologist. 
2.To assess the Risk factor for Bacterial colonisation  
3.To evaluate the Airway inflammation and its relation with colonisation 
Broncho alveolar lavage was done as invasive procedure in 90 
patients with bronchiectasis and from 6 patients admitted with chronic 
upper respiratory symptoms as laboratory control in Interleukin-8 
estimation. 
Patients were selected randomly 
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STUDY PERIOD 
This study was done for a period of 7 months from 
February 2014 to August 2014 
STUDY POPULATION: 90 patients 
STUDY CENTRE  
This study was done in Rajiv Gandhi Govt General Hospital, 
Madras Medical College, Chennai-03 
 
 
 
 
 
 
 
 
 
 
40 
 
INCLUSION CRITERIA: 
1.Patients admitted with HRCT Chest diagnosis of Bronchiectasis{non 
cystic fibrosis} 
2.Age >14 years  
3.SpO2> 90% in Room air 
EXCLUSION CRITERIA 
1.Patients with complications like Hemoptysis, Lung abscess and 
Amyloidosis. 
2.patients with Cystic fibrosis.  
3.SPO2<90% in room air. 
4.Patients with prior Hospitalisation within 2 months and had antibiotic 
within 4 weeks. 
5.Patients with cardiac illness and Recent Myocardial infection  
 6. Patients with Renal failure 
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MATERIALS AND METHODS 
Proforma was designed and ethical committee clearance 
was obtained. 
The nature and purpose of the study was explained in 
detail to all the study Patients and written informed consent was 
obtained from all of them included in this study. 
Data collection was done as per the proforma  
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STUDY PROCEDURE: 
Patients admitted with HRCT Chest taken within 3 months and 
confirmed bronchiectasis were studied with 
1.Sputum for- 
a)Modified Zhiel Neelson staining for Acid Fast Bacilli smear in RNTCP 
Lab 
b)Bacterial culture and sensitivity in Microbiological Lab 
c)Gram staining in Microbiology Lab 
2.Spirometry to asses Pulmonary Function 
3.Broncho alveolar lavage with Fiber optic bronchoscope 
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METHODOLOGY 
Patients admitted with HRCT Chest evidence of Bronchiectasis 
taken within 3 months duration were evaluated for study after inclusion 
and exclusion criteria analysis. Informed consent was obtained from all 
the patients and from parents of patients with age <18 years. The study 
purpose and methods, procedures were all explained to the patients in 
their mother tongue. On the day of admission after obtaining complete 
clinical history and complete clinical examination was done; the type of 
bronchiectasis as per Reid classification was noted and HRCT Chest 
scoring was done as per Reiff and Colleagues criteria; and after doing 
base line investigation, sputum was given for 2 samples for Acid fast 
bacilli smear in RNTCP Lab, and One sample for bacterial culture 
sensitivity and Gram staining in Microbiology lab . Good quality sputum 
was accepted as per the Murray Washington grade V classification. Other 
criteria used for clinically assessing good quality sputum-was Barlette 
criteria which consists of a) Mucus b) Mucopurulent c) Purulent d) Blood 
stained -four types of sputum . In which Purulent type sputum yielded 
high bacterial culture growth rate and considered as good quality sputum. 
After sputum culture, patients were allowed to undergo pulmonary 
function test with spirometry. 
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Pulmonary function test: 
 Spirometry was performed using a computerized Easy one 
spirometer.Patient was made to sit or erect and asked to wear a nose clip 
and spirometry was performed fulfilling the acceptability and 
reproducibility criteria according to American thoracic society 
recommendation.31 
The parameters measured in spirometry include Forced Vital 
Capacity (FVC), Forced expiratory volume in 1 second (FEV1), ratio of 
FEV1 to FVC (FEV1%). 
Lung function impairments were classified as  
1.Normal spirometry: 
FEV1 and FVC>80% and FEV1/FVC>70% predicted. 
2.Obstructive pattern: 
FEV1<80% and FEV1/FVC<70% predicted. 
3.Restrictive pattern : 
FEV1 and FVC <80% and FEV1/FVC ratio >70% predicted. 
4.Mixed pattern: 
FEV1 and FVC<80% and FEV1/FVC ratio<70%. 
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The Bronchoalveolar lavage was done on the next day of 
admission. Topical anaesthesia was achieved by nebulisation of 8ml of 
5%Lignocaine for 15 minutes. Bronchoalveolar lavage was done with 
150 ml of 0.9%Normal saline divided into three alliquots each consists of 
50 ml. Broncho alveolar lavage was done with Pentax 18P Fiber optic 
bronchoscope [pentax india private ltd] from Bronchiectasis affected part 
of lung which was identified as per HRCT Chest. About 60-70% of 
administered fluid is aspirated. The obtained fluid was mixed well in a 
single sterile container and divided into three parts and patients were 
managed with standard treatment protocol. 
First part was sent to Microbiology lab for bacterial culture 
The samples were serially diluted [dilutions of 1:10, 1:100, 1:1000] 
and plotted in Blood agar, Nutrient broth agar, Chocolate agar,Wilkins-
Chalgren ,and Saburauds agar.The cultures were evaluated for growth 
after 48 hours .Negative cultures for Bacteria were discarded after 5 days 
and for Fungi after 4 weeks. Susceptibility testing was performed using 
broth micro dilution or Beta lactamase test and classified as sensitive and 
as Resistant as per the National committee for clinical laboratory 
standards, Performance standards for antimicrobial susceptibility testing.5 
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Second part was sent to Pathology lab for Cell Count[Total and 
Differential cell count] estimation;- The obtained fluid was assessed 
macroscopically for colour and volume, and the fluid was filtered with a 
layer of sterile gauze and centrifuged for 15 to 20 minutes at 500g and 
then resuspended in sterile saline. Total count was assessed in Newbauer 
chamber. Direct smear and cytopsin smear were prepared. The cytopsin 
preparation was centrifuged at 200g for 6minutes. The cytopsin smear 
was air dried. Both direct and cytopsin smear were stained with modified 
wright stain. About 100 to 200 nucleated cells from 5 or more fields of 
cytopsin preparation were examined in 100xlens for differential cell 
count47-49. 
Third part was centrifuged and stored in Temperature 2 to 4 
degree Celsius for IL-8 estimation. After obtaining 90 samples from 
Bronchiectasis patients and six samples from patients presented with 
upper respiratory tract symptoms [as laboratory control] ; all the 
centrifuged and stored samples were submitted for Interleukins estimation 
in National Institute of Research in Tuberculosis[NIRT] Chennai by Elisa 
method with RayBio Human IL-8 ELISA[Enzyme linked immunosorbent 
assay] Kit. 
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INTERLEUKIN-8 ESTIMATION: 
ELISA PROCEDURE 
IL-8 levels in BAL fluid samples were measured using ELISA 
(Ray Bio Human IL8 ELISA Kit) as per the manufacturer’s instructions. 
Briefly the steps include: 
1.All reagents and samples were brought into room temperature (18-25 
degree Celsius )before use. 
2.Preparation of standard 
Briefly spin the vial of Human IL-8 standard.800 micro litre 1x 
assay diluent buffer was added into human IL-8 standard vials to prepare 
50ng/ml standard. The powder was dissolved thoroughly by gentle 
mix,10 microliter IL-8 standard from the vial of human IL-8 standard into 
a tube with 823microliter of assay diluent buffer to prepare a 600pg/ml 
stock standard solution. 400microlitre 1x assay diluent buffer to prepare a 
600pg/ml stock standard solution. 400 microlitre 1x assay diluent buffer 
was added into each tube. Using the stock standard solution a dilution 
series was produced as below. Each tube was mixed thoroughly before 
the next transfer. 1x assay diluent buffer served as the zero standard (0 
pg/ml) 
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Preparation of BAL Sample 
All samples were centrifuged at 2000 rpm for 10 minutes, 100 
microlitre of supernatant was diluted with equal volume ( diluent 
factor:2) of 1x assay diluent buffer before use. 
3.Addition of sample/standard 
100 microlitre of each standard and sample was added into 
appropriate wells. Plate was covered well and incubated overnight at 
4degree Celsius with gentle shaking. 
4.Addition of secondary antibody 
The solution was discarded and washed 4 times with 300 microlitre 
of 1x wash buffer. For every wash plate was inverted and blot it against 
clean paper towels. 100 microlitre 1x prepared biotinylated antibody was 
added to each well and incubated for 1 hour at room temperature with 
gentle shaking. 
5.Conjucate addition 
After incubation the plates were washed as in stage 4, to each well 
100 microlitre of conjucate (streptovidin-horse radish peroxidase was 
added in 1 in 600 dilutions and incubated at room temperature for 45 
minutes with gentle shaking. 
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6.Substrate addition 
The plates were again washed and 100 microlitre of 
substrate TMB, one step substrate reagent was added to each 
well and incubated at room temperature for 30 minutes till the 
blue colour developed with gentle shaking. 
7.Arresting the reaction 
The reaction then was stopped using 50microlitre of stop solution. 
The optical density was measured at 450 nm on ELISA reader (molecular 
devices USA), the mean of the sample values were subtracted from the 
reading. The unknown concentration of cytokines in the samples were 
evaluated by plotting the unknown optical density values against the 
standard curve. The IL-8 concentration in BAL samples were determined 
by referring to a standard curve and expressed as pg/ml. 
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STATISTICAL ANALYSIS 
All the collected data’s were incorporated into microsoft XL 
sheets, statistical analysis was done with the help of a professional 
statistician. Broncho alveolar lavage fluid culture as the gold standard, the 
BAL fluid culture was analysed with demographical factors and 
inflammatory cells including Interleukin-8 with Fischer scale. 
 
Fischer exact p value = < 0.05 is considered as high significant  
 > 0.05 is considered as weak significant. 
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
Table 1: Showing age distribution 
Age in years Frequency Percent(%) 
16-25 years 10 11.1 
26-35 years 17 18.9 
36-45 years 29 32.2 
46-55 years 15 16.7 
56-65 years 16 17.8 
66-75 years 3 3.3 
Total 90 100 
 
Among the 90 patients in the study group starting from 16 years to 
75 years; the patients with age 36-45 years were presented in majority 
(32% ) followed by age group in 26-35 years , followed by56-65 years 
,followed by 46-55 years, followed by 16-25 years and lastly 66-75 years 
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Chart 1: Bar diagram showing age distribution 
 
Among the 90 patients in the study group starting from 16 years to 
75 years; the patients with age 36-45 years were presented in majority 
(32% ) followed by age group in 26-35 years , followed by56-65 years 
,followed by 46-55 years, followed by 16-25 years and lastly 66-75 years 
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SEX DISTRIBUTION 
 
Table 2: Showing sex distribution: 
Sex Frequency Percent(%) 
Male 38 42.2 
Female 52 57.8 
Total 90 100.0 
 
Among the 90 patients in this study population 57.8% were females and 
42.2% were males 
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Chart 2: Pie diagram showing sex distribution 
 
Among 90patients, 58% 0f patients were females and 42% of 
patients were males  
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DURATION OF SYMPTOMS 
Table 3 : Showing description of duration of symptoms with 
bronchoalveolar Lavage fluid culture 
Symptom 
duration 
No 
growth 
Percent 
% 
Non 
PPM 
Percent 
% 
PPM 
Percent 
% 
< 1 year 
N=6/6.6% 
5 83.5% 1 16.5% 0 0.0 
1-5 years 
N=59/65.4
% 
15 25.4% 3 5.6% 41 69% 
> 5 years 
N=25/27% 
1 3.7% 2 8.3% 22 88% 
 
Based on the duration of symptoms at the time of admission, a) 
65% of patients had symptoms from 1 year to 5 years; and their BAL 
fluid culture reported as no growth in 25% of patients, 5.6% positive for 
NonPPM growth and 69% were positive for PPM growth 
b) 27% of patients had symptoms more than 5 years maximum up to 30 
years; and their BAL fluid culture reported as 88% positive for PPM 
growth, 8% positive for NonPPM growth and 4% were no growth. 
c) 6.6% of patients had symptoms less than 1 year and 83.5% of their 
BAL fluid cultures were reported as no growth. 
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SMOKING DISTRIBUTION 
Table 4 : Showing distribution of patients with smoking history 
Smoking Frequency Percent (%) 
Smoker 11 12.2 
Ex smoker 6 6.7 
Non smoker 73 81.1 
Total 90 100.0 
 
Out of 90 patients in this study population 12% were smokers and 6.7 
were past smoker and 73% were non smoker 
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ALCOHOLISM DISTRIBUTION 
 
Table 5 : Showing distribution of patients with history of alcoholism 
 
Alcoholism Frequency Percent (%) 
Alcohol consumer 12 13.3 
Ex alcoholism 4 4.4 
Non alcoholic 74 82.2 
Total 90 100.0 
 
Out of 90 patients in this study population 13.3% were alcohol 
consumers and 4.4% were past alcoholism history and 82 % were non 
alcoholic. 
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Chart 3: Showing Smoking & Alcoholism distribution 
 
Among the 90 patients, 11 patients were smoker,6 patients were 
exsmoker and 12 of them were alcoholic and 4 of them were exalcoholic 
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SPUTUM GRAM STAINING 
 
Table 6 : Showing the sputum gram staining results 
 
Normal 
Throat 
commensal 
Gram 
positive 
cocci 
% 
Gram 
negative 
bacilli 
% 
Mixed-
both gram 
+ve and 
gram -ve 
% 
29 16 19% 42 47% 3 3.3% 
 
Showing among the 90 patients, the sputum gram staining reported 
as, the 29 patients sputum samples contained the normal throat 
commensals and 19% were contained gram positive cocci and 47% were 
contained gram negative bacilli and 3.3% samples were contained both 
gram positive cocci and gram negative bacilli. 
 
 
 
 
60 
 
AETIOLOGICAL DISTRIBUTION 
Table 7 : Showing Aetiological distribution 
Aetiology  Frequency Percent (%) 
Idiopathic 38 42.2 
Post infectious 19 21.1 
Post Pulmonary TB 9 10.0 
Congenital(undiagnosed) 7 7.8 
MCTD 4 4.4 
Rheumatoid arthritis 3 3.3 
Kartagener syndrome 2 2.2 
Sjogren syndrome 2 2.2 
Young’s syndrome 1 1.1 
Cong.Hypogamaglobulinemia 1 1.1 
CVID 1 1.1 
Post aspiration 2 2.2 
? Occupational 1 1.1 
Total 90 100.0 
 
[CVID-common variable immuno deficiency, MCTD-mixed 
connective tissue disease.] 
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Among 90 patients in this study population, regarding aetiology of 
Bronchiectasis Idiopathic bronchiectais were 42%, Post infectious 
bronchiectasis were 21% , Congenital type in which undiagnosed 
aetiology were 7.8% and secondary to connective tissue disease and 
kartagener syndrome, Common variable immuno deficiency 3% 
respectively . 
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BRONCHIECTASIS- RADIOLOGICAL TYPES 
 
Table 8 : Showing the radiological types of Bronchiectasis 
 
Bronchiectasis type Frequency Percent (%) 
Cylindrical 48 53.3 
Cystic 32 35.6 
Traction bronchiectasis 3 3.3 
Varicose 4 4.4 
Cystic & Cylindrical 2 2.2 
Traction& Cylindrical 1 1.1 
Total 90 100.0 
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Chart 4: Showing radiological types of Bronchiectasis 
       
Among the 90 patients in this study Cylindrical types were 53% , 
Cystic types were 35%, Varicose types were 4.4% , Traction 
bronchiectasis were 3% and 3% were mixed types i.e. Cystic plus 
cylindrical and Traction plus cylindrical. 
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PULMONARY FUNCTION FEV1% DISTRIBUTION 
 
Table 9 : Showing pulmonary function FEV1 % distribution: 
 
FEV1 in  
Spirometry 
 
Frequency 
 
Percent % 
>80 % 13 14.4% 
70-79% 10 11.1% 
50-69% 52 58% 
<50 % 15 16.5% 
Total 90 100.0 
 
 
Table:10 : Showing Spirometry pattern distribution 
 
Spirometry pattern Frequency Percent % 
Normal 13 14.1% 
Obstructive 58 64% 
Restrictive 14 15% 
Mixed 6 6.6% 
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Chart:5 – Spirometry pattern distribution showing Normal 
spirometry in 14% of patients, Obstructive pattern observed in 64% of 
patients, Restrictive pattern observed in 15% of patients and mixed 
pattern was observed in 7% of patients 
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Chart 6: Showing pulmonary function FEV1 distribution 
 
Out of 90 patients in this study 14% of patients had FEV1 > 80%, 
11 % of patients had FEV1 80-79%, 52% of patients had FEV1 50-69% 
and 15% of patients had FEV1 <50%; Normal spirometry in 14% of 
patients, Obstructive pattern observed in 64% of patients, Restrictive 
pattern observed in 15% of patients and mixed pattern was observed in 
7% of patients 
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HRCT SCORE DISTRIBUTION 
Table 11 : Showing distribution of HRCT score. 
HRCT Score Frequency Percent (%) 
< 33% 60 66.7 
33-50% 22 24.4 
> 50% 8 8.9 
Total 90 100.0 
 
 
Chart 7: Showing HRCT Score Distribution 
 
Among the 90 patients in this study, 66 % patients were presented 
with HRCT score <33%, 24% patients were presented with 34-50% and 
8.9% patients were presented with above 50%. 
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> 50 %, 8
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SPUTUM MICROBIOLOGY DISTRIBUTION 
Table 12 : Showing the micro organisms distribution in Sputum culture 
Micro organism grown[>10x5cfu] Frequency Percent (%) 
No Growth 29 32.2 
Hemophilus influenza 13 14.4 
Pseudomonas aeruginosa 11 12.2 
Streptococcus pneumoniae 9 10.0 
Klebsiella pneumoniae 6 6.7 
Staphylococcus aureus 5 5.6 
Morexella catarrhalis 4 4.4 
Acinetobacter species 3 3.3 
Klebsiella oxytacea 2 2.2 
Proteus mirabilis 1 1.1 
Escherichia coli 1 1.1 
Enterococcus 3 3.3 
Streptococcus viridans 1 1.1 
Coagulase negative staphylococcus 
aureus 
2 2.2 
Total 90 100.0 
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Out of 90 patients in this study the micro organisms isolated in 
sputum culture were, Potentially pathogenic micro organisms [PPM] 
61%, Non potentially pathogenic micro organisms[Non PPM] were 6.6% 
and No growth in 32% of patients.  
InPPM(potentially pathogenic micro organisms) the following 
micro organisms were isolated  
1.Hemophilus influenza were 14.4% 2. Pseudomonas aeruginosa 12%, 
3.Streptococcus pneumoniae 10%, 4.Klebsiella pneumoniae 6.7%, 
5.Staphylococcus aureus 5.6% , 6.Morexella catarrhalis 4.4%, 
6.Acinetobacter species 3%, 7.Klebsiella oxytacea 2%, 8.Proteus 
mirabilis 1% and Escherichia coli 1%.  
The Non PPM isolated were 1.Enterococcus 3.3% , 2.Coagulase negative 
staphylococcus 2.2% 3. Streptococcus viridans 1%. 
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BRONCHO ALVEOLAR LAVAGE FLUID CULTURE 
DISTRIBUTION 
Table 13 : Showing the micro organisms distribution in Broncho alveolar 
lavage fluid.[10x3 cfu] 
Micro organism grown Frequency Percent(%) 
No Growth 21 23.3 
Hemophilus influenza 15 16.7 
Pseudomonas aeruginosa 14 15.6 
Streptococcus pneumoniae 9 10.0 
Klebsiella pneumoniae 4 4.4 
Staphylococcus aureus 2 2.2 
Morexella catarrhalis 4 4.4 
Acinetobacter species 2 2.2 
Klebsiella oxytacea 3 3.3 
Proteus mirabilis 1 1.1 
Escherichia coli 1 1.1 
Coagulase negative staphylococcus aureus 2 2.2 
Enterococcus 2 2.2 
Streptococcus viridans 2 2.2 
Hemophilus parainfluenza+MRSA 1 1.1 
MRSA+Acinetobacter species 2 2.2 
H.influenza+Pseudomonas aeruginosa 1 1.1 
Staph.aureus+Pseudomonas aeruginosa 2 2.2 
CONS+Pseudomonas aeuruginosa 2 2.2 
Total 90 100.0 
[MRSA-methicillin resistant staphylococcus aureus] 
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Out of 90 patients in this study the micro organisms isolated in 
broncho alveolar lavage fluid culture were, potentially pathogenic micro 
organisms [PPM] 70%, Non potentially pathogenic micro organisms 
[Non PPM] were 6.6% and No growth in 23%. 
InPPM the following micro organisms were isolated 
1.Hemophilus influenza were 16.7% 2. Pseudomonas aeruginosa 15.6%, 
3.Streptococcus pneumoniae 10%, 4.Klebsiella pneumoniae 4.4%, 
5.Staphylococcus aureus 2.2% , 6.Morexella catarrhalis 4.4%, 
6.Acinetobacter species 2%, 7. Klebsiella oxytacea 3%, 8.Proteus 
mirabilis 1% and Escherichia coli 1%. 
The Non PPM isolated were 1.Enterococcus 2.2%, 2.Coagulase 
negative staphylococcus 2.2% 3. Streptococcus viridans 2.2%.In 9% 
patients, two different pathogenic bacteria were isolated i.e. Pseudomonas 
with acinetobacter and Hemophilus influenza and Coagulase negative 
staphylococcus aureus. 
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TOTAL CELL COUNT in BRONCHO ALVEOLAR LAVAGE 
FLUID 
 
Table 14 : Showing the Total cell counts in broncho alveolar lavage fluid 
Micro organisms grown 
 
Micro organisms 
grown 
Total cell count in 
range x103 
Total cell count in 
median x103 
PPM Positive         =  63 90 to 210 cellsx103/ml  120 cells x103/ml 
Non PPM positive =  06 50 to 220 cellsx103/ml 90 cells x103/ml 
No growth              =  21 40 to 180 cells x103/ml 50 cells x103/ml 
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DESCRIPTION OF TOTAL COUNTS in BAL FLUID 
 
 
Table 15 : Showing the analysis of Total cell counts in broncho alveolar 
lavage fluid. 
 
Growth 
pattern No. of patients 
Mean cell 
count[x103] 
Standard 
deviation 
PPM 63 154.92 41.246 
Non PPM 6 111.67 54.924 
No growth 21 55.38 15.167 
Total 90 128.81 56.400 
 
Difference between groups by ANOVA, p=0.0001 
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Chart 8: Showing the Total cell count in BAL Fluid 
 
Out of 90 patients in this study, the Total cell counts calculated in 
broncho alveolar lavage fluid were listed as below. 
 
In PPM patients: 90-220x103 cells in range and 120 x103 cells in median;  
 
In Non PPM patients were 50-220x103 cells in range and the 
median cell counts were 90x103 cells and in no growth patients were 40-
180x103 cells and 50x103 cells in median 
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DIFFERENTIAL CELL COUNTS in BAL FLUID 
 
Table 16 : Showing differential cell counts in broncho alveolar lavage 
fluid 
Predominant cells No of patients 
 
Percent (%) 
 
Neutrophils >50% 44 
49% 
 
Lymphocytes>50% 40 
44% 
 
Mixed[Both cells in equal] 06 
07% 
 
 
 
Among the 90 patients in this study population the differential cell 
counts calculated in broncho alveolar lavage fluid were 1.Neutrophils 
>50% of total count in 44 patients , Lymphocytes >50% of total counts in 
40 patients and in 6 patients both Neutrophils and Lymphocytes were in 
equal proportion. 
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DESCRIPTION OF DIFFERENTIAL CELL COUNTS 
Table 17 : Showing the differential cell counts in broncho alveolar lavage 
fluid. 
Cell pattern Growth type 
No.of 
patients Mean Std.deviation 
Neutrophils > 
50% 
PPM 63 46.59 16.530 
Non PPM 6 49.17 10.206 
No growth 21 44.05 15.217 
Total 90 46.17 15.812 
Lymphocytes > 
50% 
PPM 63 44.52 13.581 
Non PPM 6 45.00 8.367 
No growth 21 47.62 13.474 
Total 90 45.28 13.226 
 
Difference between groups (Neutrophils) by ANOVA, p=0.731 
Difference between groups (Lymphocytes) by ANOVA, p=0.654 
 
Among the 90 patients in this study population the differential cell 
counts calculated in broncho alveolar lavage fluid were 1.Neutrophils 
>50% of total count in 44 patients , Lymphocytes >50% of total counts in 
40 patients and in 6 patients both Neutrophils and Lymphocytes were in 
equal proportion. 
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INTERLEUKIN-8 DESCRIPTION in BAL FLUID 
Table 18: Showing the interleukin 8 levels in broncho alveolar lavage 
fluid. 
Growth 
type 
No.of 
patients 
IL-8 in 
Range. 
pg/ml 
Mean Standard deviation 
PPM 63 220 -835 556.95 133.604 
Non PPM 6 220-770 651.67 222.478 
No growth 21 81-320 155.81 83.816 
Total 90 81-835 463.67 214.394 
Control 6 2-7 5  
 
Difference between groups by ANOVA, p=0.0001 
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Chart 9: Showing Interleukin – 8 descriptions in BAL fluid 
 
Out of 90 patients in this study the interleukin 8 estimated were 
1.in PPM patients 220-835pg/ml in range and 556pg/ml in mean: in Non 
PPM patients were 220-770pg/ml and 561pg/ml in mean and in No 
growth patients were 81-320pg/ml and 155pg/ml in mean. 
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COMPARING BAL GROWTH WITH AGE DISTRIBUTION 
Table 19 : Showing the Broncho alveolar lavage with age distribution 
comparison 
Age in 
years 
PPM    Non PPM No Growth 
Total 
N 
% in 
Age 
group 
N 
 
% in 
Age 
group 
N 
 
% in 
Age 
group 
16-25 5 50.0% 2 20.0% 3 30.0% 10/ 100% 
26-35 11 64.7% 1 5.9% 5 29.4% 17/100% 
36-45 22 75.9% 0 0.0% 7 24.1% 29/100% 
46-55 12 80.0% 1 6.7% 2 13.3% 15/100% 
56-65 12 75.0% 1 6.3% 3 18.8% 16/100% 
66-75 1 33.3% 1 33.3% 1 33.3% 3 /100% 
Total=90 63 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test ,  p value =0.026 
In this comparison of broncho alveolar lavage fluid culture with 
age distribution , the micro organisms growth were more in age group 36-
45 years followed by in age groups 46-55 years. 
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COMPARING BAL CULTURE WITH SEX DISTRIBUTION 
Table 20 : Showing the comparison of broncho alveolar lavage fluid 
culture with sex distribution 
Sex 
PPM Non PPM No Growth 
Total 
N % in age group N 
% in age 
group N 
% in age 
group 
M 26 68.4% 3 7.9% 9 23.7% 38 / 100% 
F 37 71.2% 3 5.8% 12 23.1% 52 /100% 
T 63 70.0% 6 6.7% 21 23.3% 90 /100% 
 
Fischer exact test , p value =0.098 
By comparing the broncho alveolar fluid culture in relation with 
sex distribution; the micro organisms growth were observed in females 
77% and males in 76% 
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COMPARING BAL CULTURE WITH SMOKING HISTORY 
 
Table 21 : Showing the comparison of broncho alveolar lavage fluid 
growth with smoking history 
Smoking 
History 
PPM Non PPM No Growth 
Total 
N % N % N % 
YES 8 72.7% 1 9.1% 2 18.2% 11/100% 
Exsmoker 4 66.7% 1 16.7% 1 16.7% 6 /100% 
NO 51 69.9% 4 5.5% 18 24.7% 73/100% 
Total 63 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test, p value =0.042 
In comparison of broncho alveolar lavage fluid culture with 
smoking history, in 72% of smokers PPM growths were observed and in 
25% of non smokers no growth was observed. 
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COMPARING BAL CULTURE WITH ALCOHOLISM 
 
Table 22 : Showing the comparison of broncho alveolar lavage fluid 
with alcoholism history. 
Alcoholism 
History 
PPM Non PPM No Growth 
Total 
N % N % N % 
YES 8 66.7% 1 8.3% 3 25.0% 12/100% 
Exalcoholic 2 50.0% 1 25.0% 1 25.0% 4 /100% 
NO 53 71.6% 4 5.4% 17 23.0% 74/100% 
Total 63 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test value, p=0.029 
In comparison of broncho alveolar fluid culture with alcoholism 
history; in 87 % of patients with alcoholism PPM and Non PPM growths 
were observed and in 13% of non alcoholic patients, No growths were 
observed. 
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COMPARING BAL CULTURE WITH FEV1% 
 
Table 23 : Showing the broncho alveolar culture comparison with 
pulmonary function FEV1% 
FEV1% 
PPM Non PPM No Growth 
Total 
N % N % N % 
> 80% 4 30.8% 1 7.7% 8 61.5% 13/100% 
70-80% 5 50.0% 2 20% 3 30% 10/100% 
50-70% 40 76.9% 3 5.8% 9 17.3% 52/100% 
Total 63 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test value, p=0.001 
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COMPARING FEV1 WITH MICRO ORGANISM GROWTH 
 
Table 24 : Showing statistical analysis of FEV1 with micro organisms 
 
Growth Type N Mean Std. deviation 
PPM 63 58.06% 12.025% 
Non PPM 6 68.17% 10.591% 
No Growth 21 70.57% 11.565% 
Total 90 61.66% 12.956% 
 
Difference between groups by ANOVA, p =0.0001 
  
85 
 
 
 
Chart 10: Showing Comparison between FEV1 with BAL Culture 
 
In comparison of broncho alveolar lavage fluid culture, among  90 
patients 14% of patients were with FEV1 more than 80% in which all 
were negative growths in BAL culture, 11% of patients were with FEV1 
80 to 70% (in which 4% were negative growth, 7% of patients were Non 
PPM positive growth in BAL culture) and remaining 75% of patients 
were with FEV1 less than 70% (in which 70% of patients were positive 
for PPM growth and 5% of patients were negative growth in BAL 
culture). 
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COMPARING BAL CULTURE WITH HRCT SCORE 
 
Table 25 : Showing the comparison of broncho alveolar lavage fluid 
culture with HRCT score 
 
HRCT 
Score 
PPM NonPPM No Growth 
Total 
N % N % N % 
< 50% 42 63.6% 5 7.6% 19 28.8% 66/100% 
> 50% 21 87.5% 1 4.2% 2 8.3% 24/100 
Total 67 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test value, p=0.009 
By this comparison of broncho alveolar lavage fluid culture with 
HRCT score; >50% score was associated with 87.5% PPM growths and 
in HRCT score <50% was associated with 29% of No growths. 
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COMPARING BAL CULTURE WITH BRONCHIECTASIS 
TYPES 
Table 26 : Showing the comparison of broncho alveolar lavage fluid 
culture with radiological types of bronchiectasis. 
Bronchiectasis 
Types 
PPM NonPPM No Growth 
Total 
N % N % N % 
Cylindrical 28 58.3% 4 8.3% 16 33.3% 48/100% 
Cystic 27 84.4% 1 3.1% 4 12.5% 32/100% 
Traction 2 66.7% 0 0.0% 1 33.3% 3 /100% 
Varicose 3 75.0% 1 25.0% 0 0.0% 2 /100% 
Cystic+cylindrical 2 100.0% 0 0.0% 0 0.0% 2 /100% 
Traction+cylindrical 1 100.0% 0 0.0% 0 0.0% 1 /100% 
Total 63 70.0% 6 6.7% 21 23.3% 90/100% 
 
Fischer exact test value, p= 0.006 
In comparison of broncho alveolar lavage fluid culture with 
bronchiectasis types; Cystic bronchiectasis was associated with 84% 
positive growth followed by varicose bronchiectasis 75%; and Cylindrical 
and Traction bronchiectasis was associated with 33% of negative growth 
respectively. 
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COMPARING SPUTUM & BAL CULTURE RESULTS 
 
Table 27: Showing the comparison of sputum and broncho alveolar 
lavage fluid culture. 
SPTUM_C_S 
 BAL _C_S_CAT 
Total 
 PPM NonPPM No growth 
PPM=55 
No.of pts 54 1 0 55 
Percent 98.2% 1.8% 0.0% 100.0% 
Non PPM=6 
No.of pts 2 4 0 6 
Percent 33.3% 66.7% 0.0% 100.0% 
No 
Growth=29 
No.of pts 7 1 21 29 
Percent 24.1% 3.4% 72.4% 100.0% 
Total 
No.of pts 63 6 21 90 
Percent 70.0% 6.7% 23.3% 100.0% 
 
Observed agreement: 0.877778  
Expected agreement: 0.507407 
k coeff : 75.18797 
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In detailed analysis of sputum and broncho alveolar lavage fluid 
culture ; the negative growth was observed in 29 sputum samples and 21 
broncho alveolar lavage fluid samples, and 21 samples (both sputum and 
broncho alveolar lavage fluid) were negative growth pattern; In regarding 
positive growth, 61sputum samples were positive growth and 69 broncho 
alveolar lavage samples were positive growth and the 55 samples of both 
sputum and broncho alveolar fluid sample were same micro organisms 
pattern having concordant value of 75%. 
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SUMMARY 
 
Among the 90 patients in this study population 29% of patients 
were in age group between 36-45 years, 16% were in between 56-65 
years, 15% were in between 46-55 years and 10% were between 16-25 
years: Females were 58% and males were 42%:  
 
Regarding personal habits 12 % of patients were smokers, 7% were 
past smokers and 81% of patients were never smokers: 13% of patients 
were alcohol consumers and 5% were past alcohol consumers and 82% 
were not alcohol consumers. 
 
Regarding aetiology of bronchiectasis ,42% of bronchiectasis were 
idiopathic , 21% were due to post infectious , 10% were due to post 
pulmonary tuberculosis , undiagnosed cause of congenital types were 8% 
and mixed connective tissue disease 11%, and diagnosed congenital 
causes [kartagener syndrome, young's syndrome, and immuno deficiency 
states ]5%. 
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Regarding radiological types of bronchiectasis, Cylindrical types 
were 53%, Cystic 35%, and Varicose types 4%: and depending upon the 
disease severity in HRCT chest, HRCT score was calculated. Among 90 
patients, 67% of patients were <33%, 24% were 34-50% and 9% of 
patients were >50%. 
 
Regarding the pulmonary function measured by FEV1% in 
Spirometry; normal spirometry measured in 14% of patients, obstructive 
pattern measured in 64% of patients [with FEV1- 70-79%= 11% of 
patients, with FEV1 50-69%= 49.6% of patients and with FEV1 <50% 
=4.4% of patients]. Restrictive pattern was observed in 15% of patients 
[with FEV1<70 in 3 patients and with FEV1<50% in 11 patients] and 
Mixed pattern [both obstruction+restriction] was observed 7% of patients. 
 
Regarding the micro organisms isolated in sputum and broncho 
alveolar lavage culture, Positive sputum culture growths were 68%, 
negative culture growths were 32%: In Broncho alveolar lavage fluid 
culture, positive culture growths were 77% and negative culture growths 
were 23%. The predominant organisms isolated were 1.H.influenza 
2.Pseudomonas species 3.Streptococci pneumoniae 4.Staphylococcus 
aureus 5.Morexella catarrhalis 6. Klebsiella species etc.  
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Regarding inflammation of airways in bronchiectasis, the total 
counts were raised in potentially pathogenic micro organisms grown 
patients followed by nonpotentially pathogenic micro organisms grown 
and lesser amounts in patients with no growth. The differential cell count 
Neutophils more than 50% of total count was observed in 44 patients 
,Lymphocytes more than 50% were observed in 40 patients and both 
Neutrophils and Lymphocytes in equal portion in 6 patients indicating 
slight increase of Neutrophilic pattern followed by Lymphocytic pattern. 
 
The interleukin-8 measured in BAL fluid showed, the increased 
level [range 81-835pg/ml , from no growth to PPM growth] was observed 
in all the three groups i,e in PPM , NonPPM and No Growth patients with 
comparing 6 controls ranged from 2-7pg/ml, indicating the earlier 
establishment of airway inflammation and the airway inflammation was 
worsened by micro organisms colonisation. 
Regarding the risk factor for micro organisms colonisation, the increased 
risk was observed in patients presented with 
 
1. Long duration of symptoms > 5 years 
2. with habits of smoking and alcoholism 
3. Cystic bronchiectasis and varicose bronchiectasis 
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DISCUSSION 
DEMOGRAPHICAL FACTORS 
Based on the guidance studies, David A Bergin et al study, J 
Angrill et al study, C Agusti et al study, U.S study of investigation into 
aetiology of bronchiectasis; in this study closely matched with the above 
studies in demographical description11,12,20 , except the median age in this 
study was 42 years against 65 years and 58 years in above studies. 
Females were 58%, males were 42%; smokers and alcohol consumers 
were 19%. 
 
The predominant radiological type of bronchiectasis was 
cylindrical(53%) followed by cystic bronchiectasis(35%); and regarding 
the aetiology of bronchiectasis, idiopathic bronchiectasis(42%), post 
infectious(21%), post pulmonary tuberculosis(10%), and 2-3% of 
kartagener syndrome, young's syndrome, common variable 
immunodeficiency, congenital hypogammaglobulinemia and Rheumatoid 
arthritis and mixed connective tissue diseases respectively. 
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MICROBIOLOGY OF BRONCHIECTASIS 
The micro organisms from the airways of clinically stable 
bronchiectasis patients were isolated by sputum culture and broncho 
alveolar lavage fluid culture. The BAL fluid culture (77%positive growth 
rate) was slightly higher than sputum positive culture (68%).  
The micro organisms isolated from sputum and BAL culture were 
H.influenza (17%), Pseudomonas species (16%), Streptococcus 
pneumoniae (10%), Morexella, Klebsiella and Staph aureus were 3-4% 
respectively as similar to previous studies1,3,7. 
By comparing the sputum and BAL fluid culture, among the 61 (68%) 
positive culture in sputum samples; 56 samples were positive for PPM 
growth and 5 samples were positive for Non PPM growth in BAL fluid 
culture. Among the 29 negative cultures in sputum samples - 7 samples 
were positive for PPM growth and 1sample was positive for Non PPM 
growth and 21samples were found to be No growth in BAL fluid culture-
with k co efficiency of 75%. 
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In J Angrill et al study and C Agusti et al study; the positive 
sputum culture was observed in 66% of patients, in BAL-positive culture 
was observed in 79% of patients; and both techniques agreed same 
positive growth in 30 patients /60 cases, and agreed negative growth in 18 
patients /60 cases with concordant value of 75% for both techniques; this 
observation in this study fully matched with this studies.8-12 
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ANALYSIS OF BAL CULTURE WITH DEMOGRAPHIC DATA 
J Angrill et al study and C Agusti et al study evaluated the 
increased colonisation in age groups > 60 years , patients with smoking 
and alcoholism, in cystic bronchiectasis; and observed the inverse 
relationship between the airway colonisation and pulmonary function i,e 
more colonisation leads to poor pulmonary function, and similar findings 
were evaluated in this study.11,12 
 
By keeping the Broncho alveolar lavage fluid culture as gold 
standard the following analysis were done. 
AGE- The increased culture positive was observed in age group 46-55 
years (80%), 36-45 years (75%) and 26-35 years (65%). The people in 
age group between 36-55 years were presented with long duration of 
symptom i.e. more than 5 years and up to 30 years duration -co relating 
the long duration of symptoms, the micro organisms colonisation was 
high11,12. 
 
SEX: The females in this study were 52(58%) in comparison with males, 
the negative cultures observed in females were 12 /21 no growths, in 
contrast males were 9/21 no growths. 
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HABITS: Regarding the personal habits like smoking and alcoholism 17 
patients(19%) were used to smoking and alcohol ; the No growths 
observed in 18(25%) patients who were never smoker and never alcohol 
consumers and in 75% of smokers and alcoholics PPM and Non PPM 
growths were observed - co relating that smoking and alcoholism 
increases the micro organisms colonisation11,12 
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PULMONARY FUNCTION 
Among the 90 patients, normal spirometry[FEV1> 80%] was 
measured in 13 (14.4%) patients and in 53(59%) patients obstructive 
pattern (FEV1< 70%) and Restrictive pattern was observed in 14 patients 
(15%). The negative growths were observed in 18/21 of patients who had 
FEV1 >70% [14% normal spirometry +5.5% mild obstructive pattern]. 
Among the 69(77%) positive growths observed patients, patients with 
FEV1 <70% were 67(74%) with moderate obstructive pattern 53(58%) 
and severe restrictive pattern 14(15%) -co relating that micro organisms 
colonisation in the airways of bronchiectasis lead to more tissue damage 
and poor pulmonary function11,12,29,30 
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RADIOLOGICAL TYPES 
Among the 90 study patients the predominant radiological type of 
bronchiectasis was Cylindrical 48 patients (53%) Cystic 32 patients 
(36%) and Varicose type 4cases (4.4%). Among 32 cystic types 28 cystic 
bronchiectasis were positive for PPM and Non PPM growth. Among 
Varicose type the 4 patients were positive for micro organisms growth. In 
the Cylindrical type of bronchiectasis 16 patients against 48 cases were 
found to be No growths in BAL culture - co relating that micro organisms 
colonisation were more in Cystic and Varicose type39,40 . 
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RELATION BETWEEN THE COLONISATION AND 
INFLMMATION: 
J Angrill et al study and C Agusti et al study, David A Bergin et al 
study evaluated the BAL fluid inflammatory cells and the interleukins 
level in proportion with airway bacterial colonisation. The total counts 
measured were 1086x103 cells(maximum) ,and 100x103-1086x103 cells 
[in range] with Neutrophilic predominance in 66% of patients and 
Interleukin-8 level measured were 120-5520 pg/ml [in range] and 
195pg/ml in median were measured in PPM positive group; where as in 9 
control group , total counts measured were 110x103 cells with 
Neutrophilic pattern in 1% and the interleukin-8 measured were 0-
32pg/ml (in range) - indicating the increased level of inflammation in 
direct proportion with microbial colonisation11,12,23-26,32-36 
 
Regarding the total count measured in BAL fluid; there was 
increased amount of inflammatory cells in the airways of bronchiectasis 
in all the three groups i.e. in PPM, Non PPM and No growth patients. The 
mean cell counts observed were 120x103 cells for PPM patients, 90x103 
cells in Non PPM patients and 50x103 cells in No growth patients. The 
maximum cell counts measured were 220x103 cells in PPM growth 
patients. The least cell counts measured were 40x103 cells in No growth 
patients. 
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Regarding the differential cell count: Out of 90 patients in 44 patients 
(49%) the Neutrophils more than 50% of total cell count were measured, 
and in 40 patients (44%) the Lymphocytes more than 50% of total cell 
counts were measured and in 6 patients (7%) equal proportions of 
neutrophils and lymphocytes were measured. 
 
In bronchiectasis airways more cellularity was measured and there was 
slight Neutrophilic pattern followed by lymphocytic pattern. The more 
number of neutrophils leads to liberation of elastase, proteinase, tumour 
necrosis factor alpha and cytokines predominantly interleukins-8, and this 
interleukin-8 causes neutrophilic chemotaxis in airways and the net result 
of more airway inflammation and more tissue damage.32-36. 
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INTERLEUKIN-8: 
In this study interleukin-8 was measured from 6 normal people as 
control group and the values in range 2 - 7 pg/dl and 5pg/dl in mean. The 
90 patients in this study were divided into three groups i,e PPM, Non 
PPM group and No growth group. The mean values measured were 
556.95pg/dl in PPM, 561.67pg/dl in Non PPM, and 155.81pg/dl in No 
growth patients respectively. The highest level of IL-8 835pg/dl was 
measured in PPM group and the lowest value of IL-8, 81pg/dl was 
measured in patients with No growth sample. The total range of IL-8 
among the 90 patients was 81-835pg/dl. 
With this, the interleukin 8 was grossly raised in the airways of 
bronchiectasis patients irrespective of the micro organisms colonisation, 
but the peak of raise of IL-8 was higher in patients with micro organisms 
colonisation especially in potentially pathogenic micro organisms 
colonisation -indicating the earlier establishment of airway inflammation 
and the airway inflammation was worsened by the micro organisms 
colonisation especially the potentially pathogenic micro organisms.11,12,23-
26 
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CONCLUSION 
With complete analysis of entire study results, the following 
conclusions were arrived. 
1. Increased incidence of bronchiectasis in females (58%). 
2. Cylindrical bronchietasis was the commonest type followed by Cystic 
bronchiectasis 
3. Regarding aetiology of Bronchiectasis, 42% of bronchiectasis were 
Idiopathic followed by post infectious 21% 
4. The pulmonary function FEV1< 70% was associated with micro 
organisms colonisation of bronchiectatic airways.  
5. With concordant value of 75% for sputum culture and broncho alveolar 
lavage fluid culture, the Sputum culture is the non invasive, alternative 
technique for broncho alveolar lavage fluid culture. 
6. As the airway inflammation was worsened by micro organisms 
colonisation, by elimination of these micro organisms, the airway 
inflammation and tissue damage can be reduced and  
7. Following factors were identified as the Risk factors for micro 
organism’s colonisation of airways 
 a) Patients with long duration of symptoms 
 b) Associated personal habits like smoking and alcoholism 
 c) Cystic bronchiectasis and varicose bronchiectasis 
 
 
 
STUDY LIMITATION 
 
In comparing the previous studies, in this study the protective specimen 
brush technique was not done 
In Neutrophilic chemotaxis the Elastase activity is more, and various 
cytokines are liberated in the airway of bronchiectasis, this study 
measured the interleukins 8 only and not measured the other cytokines 
[TNF alpha, Myeloperoxidase,and Leukotrienes] and sputum elastase 
activity, due to cost . 
With comparing the previous studies the accuracy of data collected is 
questionable. 
Selection bias could have happened as patients represented in this study, 
all belong to a single tertiary care centre. 
Since the sample size is small, this may not represent the exact nature of 
disease in general population 
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BRONCHIAL COLONISATION AND INFLAMMATION 
IN PATIENTS WITH CLINICALLY STABLE 
BRONCHIECTASIS 
 
Name  :    IP No : 
 
Age  :    Sex   : 
 
Address :    Mobile No : 
 
COMPLAINTS : 
 
 
            Hemoptysis 
 
            Expectoration             Fever 
 
            Breathlessness             Others 
 
 
 
 
 
EXPECTORATION : W        White Mucoid             Purulent 
 
             Foul Smelling 
 
            Others 
 
 
  
 
 
Duration of Symptoms : 
 
PAST 
HISTORY : 
            Joint Pain  
            (S/o.Rneumatoid) 
 
      Dry Eyes, 
Dry     
Mouth  
      
(S/o.Sjogren 
       Fever 
 
             Exanthematous 
            Fever 
 
Recurrent cough 
and 
cold since child 
hood 
 
 
       Aspiration  
 
 
 
      Prior ATT 
    
Personal History:           Smoker          Alcoholism  
           Tobaco Chewer       Beetel nut chewer 
 
Family History :-  Cansanguinous marriage 
 
    Infertility 
 
    Other family member has similar problem 
 
Occupational History :- 
 
ON EXAMINATION 
 
Nutritional Status  Normal  Anemia 
 
    Emaciated  Obese 
 
 
 
 
Head to Foot :-  Clubbing  Comfortable 
 
    Tachypneic  Dyspneic 
 
    Pedal Edema  Ascites 
 
 
Vitals :-  RR : 
 
HR :  
 
BP : 
 
SPO2 
 
 
Temp 
 
 
 
 
Respiratory System Examination:- 
 
Investigations:- 
 
CBC  :  Total Count : 
 
 
 
Differential Count :  P :   L :   E : 
 
M :   B : 
 
Hb%   : 
 
ESR   :  ½ hr :   1 hr. 
 
Platelet  : 
 
RBC   :                                                    Spirometry 
                                                                                         FVC 
                                                                                             :                                        
                                                                                         FEV1 
B1 – Sugar  :                                                       
B1 – Urea  :                                                    FVC/FEV1 
 
Sr. Creatinine  :                                                    PEFR 
 
Total Bilirubin :                                                    FEF 25to 75 
 
Total : - Protein : 
  
   Allumin : 
 
Sputum – AFB : 
 
 
 
Sputum Culture : 
 
 ECG   : 
 
CXR   : 
 
Echocardiogram : 
 
 
HRCT Chest :- {Score -o-no bronchiectasis.1-bronchiectasis involving one 
segment/lobe .2-bronchiectasis involving >one segment/lobe. 3-cystic bronchiectasis} 
Max Score-18 
1. No. of Segments involved 
2. Pattern of branchiectasis 
       3.  Total score 
 
Rheumatologist Opinion :- 
 
Bronchiectasis Due to :- (Based on clinico radiological evidence) 
 
FOB Findings :- 
 
Broncho alveolar Lavage Fluid: 
 
1. Cell Count :                   
2. Cytology : 
3. Culture : 
4. IL-8                 : 
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1 Chandru 23 m nil nil congenital8 yrs 
8 
years 53% 41% o.63 67% 
gm -
ve ba Cystic bronchiectasis K.Pneumoniae 
Staph aureus,P 
aeuruginosa 
290 
x10*3cells/ml 
N-50%,L-
40% Not resistant to drug 760.000 
2 Vijayakumar 35 m nil nil Post infect 2 yrs 65% 69% 0.78 50% NTC Cystic bronchiectasis No growth No Growth 103X10*3 
N-60%.L-
35%   153.000 
3 Palraj 65 m present present Post PT 
15 
YRS 60% 54% 1 50% 
gm -
ve ba Cystic+ Tubular bronchiectsis Psed.aeuruginosa H.Influenza 190X10*3 
N-65%.L-
25% 
S-
AGS.Quinolone,Cepha 360.000 
4 Theivanayagi 42 f nil nil MCTD 2 yrs 65% 62% 0.76 33% 
gm 
+ve co Cylindrical Strepto pneumoniae Stepto pneumoniae 170X10*3 
N-60%L-
35% S-Quinolon,Piperacillin 450.000 
5 Savithri 35 f nil nil post infect 
15 
yrs 60% 67% 0.76 33% 
gm-ve 
ba Cystic bronchiectasis Psed.aeuruginosa K.OXYTACEA 350X10*3 
N-65%.L-
25% Cephalosporin resist 797.000 
6 Sekar 40 m 
EX 
SMOK nil Post infect 
10 
yrs 59% 65% 0.7 33% 
gm-ve 
ba cylindrical bronchiectasis Psed.aeuruginosa Psed.aeuruginosa 325X10*3 
N-50%,L-
40% S-AGS,Cefaperazone 609.000 
7 Stella mary 43 f nil nil Idiopathic 2 yrs 69% 72% 0.76 33% 
gm-ve 
ba cylindrical bronchiectasis Psed.aeuruginosa Psed.aeuruginosa 310X10*3 
N-45%,L-
50% S-AGS,Cefaperazone 807.000 
8 Nithya kalyani 35 f nil nil Post infect 5 yrs 63% 54% 0.7 33% 
gm-ve 
ba cylindrical bronchiectasis H.influenza H.influenza 150X10*3 
N-50%,L-
40% Penicillin Resistant 757.000 
9 Shyamala 39 f nil nil Idiopathic 5 yrs 59% 63% 0.77 50% 
gm-ve 
ba cylindrical bronchiectasis H.influenza H.influenza 300X10*3 
N-70%,L-
25% S-Quinolon,Piperacillin 757.000 
          
10   Gangasalam 52 m present present Karatagener 10yrs 41% 39% 0.66 67% 
gm-ve 
ba Cystic bronchiectasis Psed.aeuruginosa Psed.aeuruginosa 300X10*3 
N-65%.L-
25% Quinolon resistant 654.000 
11 Vaduvambal 50 f nil nil Idiopathic 
10 
yrs 47% 42% 0.56 17% 
gm-ve 
ba cylindrical bronchiectasis H.influenza H.influenza 200X10*3 
N-55%,L-
40% S-Erythro,amoxy 450.000 
12 Ponnaiah 42 m nil present Post infect 2 yrs 54% 51% 0.69 33% NTC Cylindrica bronchiectasis No growth No Growth 110X10*3 N25%.L60% S-AGS,Cefaperazone 207.000 
13 Geetha 42 f nil nil Idiopathic 2 yrs 63% 67% 66% 50% NTC cylindrical bronchiectasis No growth No Growth 100X10*3 
N-20%.L-
60%   81.000 
14 Paranchothi 43 f nil nil Idiopathic 5 yrs 61% 54% 0.72 33% 
gm+ve 
co cylindrical bronchiectasis Staph.aureus 
Staph aureus,P 
aeuruginosa 210X10*3 
N-70%,L-
25% S-Amoxy,Quinolon 557.000 
15 Arjunan 55 m present present Post infect 
15 
yrs 58% 52% 0.7 50% NTC Cystic bronchiectasis No growth Psed.aeuruginosa 110X10*3 
N-50%,L-
40% S-AGS only 660.000 
16 Lakshmi 45 f nil nil Rheumatoid 5 yrs 71% 69% 0.73 33% 
gm+ve 
co Tubular bronchiectasis Strepto pneumoniae Strepo.pneumoniae 120X10*3 
N-40%,L-
55% S-Erythro,amoxy 557.000 
17 Kanniammal 48 f nil nil Post TB 15yrs 50% 56% 68% 33% NTC Cystic bronchiectasis No growth H.influenza 170X10*3 
N-
55%,L35% S-Erythro,amoxy 207.000 
18 Vanaja 42 f nil nil Idiopathic 5 yrs 71% 74% 73% 33% 
gm-ve 
ba Tubular bronchiectasis H.influenza H.influenza 170X10*3 
N-50%,L-
45% Penicillin Resistant 757.000 
19 murumayee 45 f nil nil Idiopathic 2 yrs 69% 71% 77% 33% NTC Tubular bronchiectasis No growth No Growth 150X10*3 
N-20%,L-
65%   85.000 
20 Sujatha 40 f nil nil Idiopathic 5yrs 64% 68% 0.71 33% 
gm+ve 
co Cystic bronchiectasis Staph.aureus Staph aureus 190X10*3 
N-70%,L-
25% Penicillin Resistant 600.000 
         
21.   Gopal 58 m present present Post TB 
25 
yrs 51% 55% 1 50% 
gm+ve 
co Tubular+Traction bronchiectasis Strepto Pneumoniae Strepo.pneumoniae 270X10*3 
N-75%,L-
20% 
S-
Erythro,cotrimoxazole 457.000 
 
 
22 Poongodi 45 f nil nil Idiopathic 2 yrs 67% 73% 0.77 17% NTC cylindrical bronchiectasis No growth No Growth 150X10*3 
N-25%,L-
65%   81.000 
23 Kamalanathan 32 m nil nil Postinfect 
15 
yrs 49% 33% 0.65 67% 
gm-ve 
ba Cystic bronchiectasis Psed.aeuruginosa Psed.aeuruginosa 410X10*3 
N-65%,L-
30% Quinolon resistant >835 
24 Suresh 17 m nil nil Karatagener  2 yrs 67% 81% 0.77 33% 
gm-ve 
ba Cystic bronchiectasis K.Pneumoniae K.pneumoniae 260X10*3 
N-50%,L-
40% Cephalosporin resist 800.000 
25 Chandra 35 f nil nil congenital8 yrs   59% 63% 0.68 50% 
gm-ve 
ba Cystic bronchiectasis H.influenza H.influenza 220X10*3 
N-40%,L-
55% Penicillin Resistant 429.000 
26 Sathya 35 f nil nil Idiopathic 2yrs 79% 81% 0.79 17% NTC Tubular bronchiectasis No growth No Growth 140X10*3 
N-20%,L-
65%   90.000 
27 Anbu 30 m nil nil Postinfect 1 yrs 81% 85% 0.8 17% NTC cylindrical bronchiectasis No growth No Growth 150X10*3 
N-25%,L-
65%   107.000 
28 Jeyalaxmi 43 f nil nil Post TB 5 yrs 74% 69% 0.75 33% 
gm-ve 
ba Cystic bronchiectasis H.influenza H.influenza 170X10*3 
N-45%,L-
50% Penicillin Resistant 557.000 
29 Nirmala 42 f nil nil Congenital 
15 
yrs 54% 51% 0.66 50% 
gm+ve 
co cylindrical bronchiectasis Strepto pneumoniae Strepo.pneumoniae 110X10*3 
N-40%,L-
55% S-Erytho,Amoxy 459.000 
30 Suresh 22 m nil nil Postaspirat  1 yr 83% 81% 0.79 17% NTC Tubular bronchiectasis No growth No Growth 150X10*3 
N-25%,L-
65%   162.000 
31 Rathinambal 54 f nil nil MCTD 3 yrs 59% 63% 0.74 33% 
gm+ve 
co Tubular bronchiectasis Strepto pneumoniae Strepo.pneumoniae 190X10*3 
N-45%,L-
50% S-Quinolon,Piperacillin 800.000 
32 Sumathi 39 f nil nil Sjogren 5yrs 65% 61% 0.69 33% 
gm+ve 
co Tubular bronchiectasis Strepto pneumoniae Strepo.pneumoniae 230X10*3 
N-55%,L-
35% S-Quinolon,Piperacillin 550.000 
33 Vinodhini 31 f nil nil Idiopathic 2 yrs 84% 85% 0.8 17% NTC Cylindricalbronchiectasis No growth No Growth 150X10*3 
N-20%,L-
65%   107.000 
34 Vidhya 30 f nil nil CVID 
28 
YRS 39% 41% 0.63 67% 
gm-ve 
ba Cystic bronchiectasis Acinetobater species MRSA+Acinetobater 150X10*3 
N-55%,L-
40% S-Piperacillin,Quinolon 665.000 
35 Sundar 37 m present present Idiopathic 18yrs 41% 35% 0.66 67% NTC Cystic+ Tubular bronchiectsis No growth H.influenza 180X10*3 
N-40%,L-
55% S-Erthro,Amoxy 560.000 
36 Nagalaxmi 17 f nil nil Idiopathic 2 yrs 78% 81% 0.81 17% NTC Tubularbronchiectasis No growth No Growth 110x10*3 
N-20%,L-
65%   127.000 
37 Ramesh 46 m 
EX 
SMOK 
EX 
aicoho Congenita 35yrs 64% 54% 0.67 67% 
gm-ve 
ba Cystic bronchiectasis Enterococcus Enterococcus 190X10*3 
N-35%,L-
50% 
S-
cotrimaxazole,Quinolon 360.000 
38 Kalyani 43 f nil nil Idiopathic 5yrs 59% 61% 0.7 50% 
gm-ve 
ba Tubularbronchiectasis H.influenza H.influenza 120X10*3 
N-55%,L-
35% Penicillin Resistant 600.000 
39 Viswanathan 51 m nil nil Idiopathic 
15 
yrs 51% 45% 0.67 67% 
gm-ve 
ba Cystic bronchiectasis H.influenza H.influenza+Pseudom 210X10*3 
N-50%,L-
45% Penicillin Resistant 557.000 
40 Palani 75 m 
EX 
SMOK 
EX 
aicoho MCTD 3 yrs 53% 42% 1 33% NTC Cylindricalbronchiectasis No growth No Growth 150X10*3 
N-25%,L-
65%   330.000 
41 Selvi 30 f nil nil Conghypoglobulinemia     43% 37% 0.61 67% 
gm-ve 
ba Cysticbronchiectasis Psed.aeuruginosa Psed.aeuruginosa 270X10*3 
N-65%,L-
30% S-AGS,Cefaperazone 450.000 
42 Revathi 43 f nil nil Sjogren 5yrs 69% 71% 0.7 33% 
gm+ve 
co Tubularbronchiectasis Strepto pneumoniae Strepo.pneumoniae 120X10*3 
N-45%,L-
50% S-Quinolon,Piperacillin 350.000 
43 Thanikachalam 63 m 
EX 
SMOK 
EX 
aicoho Rheumatoid 2 yrs 69% 53% 1 33% 
gm+ve 
co Tubular bronchiectasis Strepto pneumoniae Strepto pneumoniae 195x10*3 
N-35%,L-
50% Not resistant to drug 457.000 
44 Krishnaveni 55 f nil nil Idiopathic 2 yrs 65% 71% 0.74 33% NTC cylindrical bronchiectasis No growth No Growth 145x10*3 
N-20%,L-
65%   97.000 
45 Anthonyammal 45 f nil nil Rheumatoid 2 yrs 69% 80% 0.79 33 NTC Tubular bronchiectasis No growth No Growth 165x10*3 
N-20%,L-
65%   107.000 
46 Govindaraj 36 m 
EX 
SMOK nil Postaspirat 5 yrs 57% 63% 0.72 33% 
gm-ve 
ba Cysticbronchiectasis Psed.aeuruginosa Psed.aeuruginosa 290X10*3 
N-70%,L-
25% S-AGS,Quinolone 600.000 
 
 
47 Rajiya 65 f nil nil Idiopathic 
30 
yrs 61% 52% 1.02 50% 
gm-ve 
ba Cystic bronchiectasis H.influenza Hparainfluenza 170X10*3 
N-65%,L-
30% S-Erythro, AGS 650.000 
48 Saroja 78 f nil nil Idiopathic 3 yrs 59% 43% 1.04 33% 
gm-ve 
ba Cylindricalbronchiectasis M.Catarrhalis M.catarrhalis 180X10*3 
N-50%,L-
50% S-Piperacillin,Quinolon 757.000 
49 Kalyanasundaram 35 m present present Idiopathic 
10 
yrs 69% 63% 0.68 47% 
gm-ve 
ba Cysticbronchiectasis K.Pneumoniae K.pneumoniae 320X10*3 
N-45%,L-
50% S-Erythro,AGS 520.000 
50 Ashok 31 m nil nil Idiopathic 5 yrs 74% 83% 0.77 17% 
gm-ve 
ba Cysticbronchiectasis H.influenza H.influenza 325x10*3 
N-35%,L-
50% S-Erythro,amoxy 757.000 
51 Nagapusanam 22 f nil nil Congenita 5 yre 76% 71% 0.72 33% 
gm+ve 
co Cylindricalbronchiectasis Enterococcus Streptoc viridans 150X10*3 
N-45%,L-
50% 
S-
cotrimaxazole,Quinolon 650.000 
52 Devi 20 f nil nil Congenita 2 yrs 84% 81% 0.8 17% NTC Cysticbronchiectasis No growth No Growth 155x10*3 
N-25%,L-
65%   320.000 
53 Sasikumar 25 m nil nil Postinfect 5yrs 85% 83% 0.8 17% NTC Tubular bronchiectasis No growth CONS 120X10*3 
N-40%,L-
55% S-methicillin,Amoxy, 220.000 
54 Ganesan 63 m nil present Postinfect 5yrs 61% 45% 1.03 33% 
gm-ve 
ba Cysticbronchiectasis Proteus species proteus species 190X10*3 
N-55%.L-
40% S-Quinolo,cotrimaxazol 540.000 
55 Veeramani 53 m nil nil Postinfect 5yrs 67% 56% 0.99 50% 
gm-ve 
ba Cysticbronchiectasis K.Pneumoniae K.pneumoniae 130X10*3 
N-60%,L-
35% Quinolon resistant 650.000 
56 Cinthamani 36 f nil nil Idiopathic 3 yrs 69% 65% 0.83 33% NTC Tubular bronchiectasis No growth No Growth 145x10*3 
N-20%,L-
65%   320.000 
57 Muniammal 60 f nil nil Idiopathic 3 yrs 67% 59% 0.73 33% NTC Cysticbronchiectasis No growth No Growth 190X10*3 
N-25%,L-
65%   107.000 
58 Madhi 57 m present present Occupational 10yrs   76% 75% 0.77 33% 
gm-ve 
ba Cylindricalbronchiectasis Enterococcus Enterococcus 120X10*3 
N-35%,L-
50% 
S-
Quinolon,cotrimoxazol 750.000 
59 Indirani 50 f nil nil postinfect 1yrs   62% 56% 0.99 33% NTC Cylindricalbronchiectasis No growth No Growth 155x10*3 
N-20%,L-
65%   230.000 
60 Malliga 45 f nil nil postinfectious 
12 
yrs 59% 60% 0.76 45% 
gm+ve 
co Cysticbronchiectasis Acinetobater species 
Acinetobacter 
specie110x10*3 120X10*3 
N-50%,L-
50% S-AGS,Piperacillin 805.000 
61 Kandasamy 60 m nil nil Post TB 5yrs 70% 69% 0.77 33% NTC Tractionbronchiectasis No growth No Growth 105x10*3 
N-20%,L-
65%   237.000 
62 Rajamani 45 m nil nil Idiopathic 5yrs 58% 63% 0.9 50% 
gm-ve 
ba Tubularbronchiectasis K.Oxytacea K.OXYTACEA 240x10*3 
N-65%,L-
30% Quinolon resistant 770.000 
63 Kannayan 53 m nil nil Idiopathic 6yrs 67% 56% 0.87 33% 
gm-ve 
ba Cylindricalbronchiectasis H.influenza H.influenza 210X10*3 
N-55%,L-
35% Penicillin Resistant 680.000 
64 Sarasu 50 f nil nil Idiopathic 5yrs 57% 49% 0.99 50% Mixed Varicose bronchiectasis CONS CONS+Acinetobacter 420x10*3 
N-60%,L-
35% Penicillin Resistant 560.000 
65 Manjula 37 f nil nil postinfection 2 yrs 81% 78% 0.78 33% 
gm-ve 
ba Tubularbronchiectasis Psed.aeuruginosa Psed.aeuruginosa 200X10*3 
N-70%,L-
25% S-AGS,Quinolone 760.000 
66 Venkatesen 35 m nil nil Idiopathic 1 yrs 84% 81% 0.77 27% NTC Cysticbronchiectasis No growth No Growth 150x10*3 
N-20%,L-
65%   107.000 
67 Rukkmani 48 f nil nil Idiopathic 5 yrs 55% 45% 0.67 33% Mixed Varicose bronchiectasis Staph.aureus MRSA+Acinetobater 210X10*3 
N-65%,L-
30% S-Vancomycin,AGS 560.000 
68 Saraswathi 50 f nil nil Idiopathic 5 yrs 65% 54% 0.98 33% 
gm-ve 
ba Tubularbronchiectasis M.Catarrhalis M.catarrhalis 190X10*3 
N-50%,L-
50% Not resistant to drug 660.000 
69 Laksmanan 27 m nil nil postinfectious 2 yrs 80% 83% 0.89 17% NTC Fusiform bronchiectasis No growth Psed.aeuruginosa 370X10*3 
N-55%,L-
40% S-AGS,Quinolone 790.000 
70 Vijayakumari 30 f nil nil Post tuberculous 3 yrs 74% 67% 0.76 33% 
gm+ve 
co Varicose bronchiectasis Staph.aureus CONS 210X10*3 
N-55%,L-
35% Quinolon resistant 770.000 
 
 
71 Anjalai 43 f nil nil Post tuberculous 2 yrs 80% 75% 0.75 27% 
gm-ve 
ba Tractionbronchiectasis E.coli E.coli 120X10*3 
N-50%,L-
40% 
S-
Quinolon,cotrimoxazol 450.000 
72 Venkatesen 30 m nil nil postinfectious 1 yrs 85% 83% o0.78 17% NTC Tubular bronchiectasis No growth H.influenza 120X10*3 
N-45%,L-
50% Not resistant to drug 770.000 
73 Mari 60 m nil nil Idiopathic 5 yrs 53% 49% 1 33% 
gm-ve 
ba Cysticbronchiectasis K.Pneumoniae K.pneumoniae 130X10*3 
N-65%.L-
25% Quinolon resistant 650.000 
74 Ettiyammal 60 f nil nil Idiopathic 
10 
yrs 56% 51% 0.99 27% NTC Cylindricalbronchiectasis No growth H.influenza 150X10*3 
N-35%,L-
50% Not resistant to drug 350.000 
75 Shanthi 36 f 
nil                  
nil   Post tuberculous 3 yrs 55% 67% 67% 42% 
gm+ve 
co Tubular bronchiectasis Strepto pneumoniae Strepto.pneumoniae 190X10*3 
N-45%,L-
50% S-Erythro,Quinolon 450.000 
76 Rajammal 55 f n nil Posttuberculous 5 yrs 61% 55% 0.98 33% 
gm-ve 
ba Cystic bronchiectasis Acinetobater species 
Acinetobacter 
specie110x10*3 185X10*3 
N-50%,L-
45% S-AGS,Piperacillin 620.000 
77 Ravi 42 m present present Idiopathic 2 yrs 73% 67% 0.88 33% NTC Tubular bronchiectasis No growth No Growth 165x10*3 
N-20%,L-
65%   120.000 
78 Desammal 57 f nil nil MCTD 2 yrs 67% 56% 0.99 27% 
gm-ve 
ba Tractionbronchiectasis K.Oxytacea K.OXYTACEA 290X10*3 
N-45%,L-
50% Quinolon resistant 432.000 
79 Selvakumar 40 m nil nil Young syndrome 
10 
yrs 59% 56% 0.76 33% 
gm-ve 
ba Cysticbronchiectasis Psed.aeuruginosa Psed.aeuruginosa 210x10*3 
N-60%,L-
35% Quinolon resistant 754.000 
80 Seeniammal 60 f nil nil Idiopathic 
12 
yrs 64% 53% 1 50% 
gm-ve 
ba cylindrical bronchiectasis H.influenza H.influenza 170X10*3 
N-55%,L-
40% Penicillin Resistant 450.000 
81 Murugesan 56 m present present Idiopathic 5 yrs 59% 53% 0.98 42% 
gm-ve 
ba Tubular bronchiectasis M.Catarrhalis M.catarrhalis 160X10*3 
N-50%,L-
40% S-Quinolon,AGS 800.000 
82 Ponmani 25 f nil nil Idiopathic 5 yrs 54% 45% 0.67 50% Mixed Cysticbronchiectasis CONS CONS+Acinetobacter 200X10*3 
N-55%,L-
40% Cephalosporin resist 770.000 
83 Ranganathan 65 m present nil postinfectious 
10 
yrs 65% 56% 1.04 33% NTC Tubularbronchiectasis No growth Psed.aeuruginosa 200X10*3 
N-35%,L-
50% S-AGS,Quinolone 320.000 
84 Thulasiammal 69 f nil nil Idiopathic 
15 
yrs 60% 59% 99% 38% 
gm+ve 
co Cylindricalbronchiectasis Streptococci viridans Streptoc viridans 180x10*3 
N-40%,L-
55% S-Erythro,amoxy 620.000 
85 Thirumalai 41 m 
EX 
SMOK 
EX 
aicoho   7 yrs 68% 58% 75% 33% 
gm-ve 
ba Cysticbronchiectasis K.Pneumoniae Psed.aeuruginosa 210X10*3 
N-55%,L-
40% Quinolon resistant >835 
86 Rajamani  56 f nil nil Idiopathic 3 yrs 73% 65% 0.97 42% 
gm-ve 
ba Tubularbronchiectasis M.Catarrhalis M.catarrhalis 170X10*3 
N-55%,L-
35% S-Quinolon,,AGS 550.000 
87 Dominiic 58 m present present Idiopathic 5 yrs 72% 67% 0.7 33% NTC Tubularbronchiectasis No growth No Growth 145x10*3 
N-30%,L-
45%   97.000 
88 Mariammal 29 f nil nil postinfectious 2 yrs 51% 54% 0.67 50% 
gm-ve 
ba Cystic bronchiectasis Psed.aeuruginosa Psed.aeuruginosa 390X10*3 
N-55%,L-
40% S-AGS,Piperacillin >835 
89 Sakthi 25 f nil nil postinfectious 2 yrs 70% 69% 0.77 33% 
gm+ve 
co Cylindricalbronchiectasis Staph.aureus Staph aureus 170X10*3 
N-65%,L-
30% S-methicillin,Amoxy, 450.000 
90 Abdullah 19 m nil nil Congenital 1 yrs 83% 81% 0.78 27% 
gm-ve 
ba Cysticbronchiectasis H.influenza Psed.aeuruginosa 290x10*3 
N-60%,L-
30% Penicillin Resistant 767.000 
                                        
  
   
gm-veba: gram negative bacilli, gm+ve co: gram positive cocci, miexd-both gram positive cocci and gram negative bacilli 
  
  
 
